Net profit of Shilpa Medicare reported to Rs 6.60 crore in the quarter ended September 2023 as against net loss of Rs 17.17 crore during the previous quarter ended September 2022. Sales rose 8.56% to Rs 74.61 crore in the quarter ended September 2023 as against Rs 68.73 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales74.6168.73 9 OPM %9.77-35.62 - PBDT24.87-11.31 LP PBT12.20-23.20 LP NP6.60-17.17 LP Powered by Capital Market - Live News

Net profit of Shilpa Medicare reported to Rs 1.61 crore in the quarter ended September 2023 as against net loss of Rs 18.66 crore during the previous quarter ended September 2022. Sales rose 19.04% to Rs 312.98 crore in the quarter ended September 2023 as against Rs 262.91 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales312.98262.91 19 OPM %18.663.80 - PBDT36.960.92 3917 PBT9.17-22.39 LP NP1.61-18.66 LP Powered by Capital Market - Live News

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 10 November 2023.Powered by Capital Market - Live News

Shilpa Medicare has acquired Pilnova Pharma, Inc in the United States on 02 November 2023 which shall be a wholly owned subsidiary of Shilpa Medicare. Powered by Capital Market - Live News

Shilpa Medicare`s finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has successfully closed-out a GMP Inspection from TGA, Australia as per communication received on 17 October 2023. The facility is involved in manufacturing, packaging, labelling, testing and release of finished dosage forms (sterile injections and non-sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy. This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years. Powered by Capital Market - Live News